Open access
3,747
Views
3
CrossRef citations to date
0
Altmetric
Oncology
An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia
Bogdan Muresana Ingress Health, Rotterdam, The Netherlands
, Carla Mamolob Pfizer Inc., Groton, CT, USAhttps://orcid.org/0000-0001-5321-561X
, Joseph C. Cappellerib Pfizer Inc., Groton, CT, USA
, Eric Leipc Pfizer Inc., Cambridge, MA, USA
, Andrea Viqueirad Pfizer SLU, Madrid, Spain
& Bart Heega Ingress Health, Rotterdam, The NetherlandsCorrespondence[email protected]
Pages 801-809
|
Received 13 Nov 2020, Accepted 24 Feb 2021, Published online: 02 Apr 2021
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.